Home  |  Speakers  |  Agenda  |  Venue  |  Posters  |  Sponsors  |  Media  |  Register


EXAMINING SCIENTIFIC, TECHNOLOGICAL, REGULATORY  & BUSINESS TRENDS & STRATEGIES  TO ADVANCE PROTEIN AND ANTIBODY THERAPEUTICS & AID BIOSIMILAR DEVELOPMENT




The 2017 agenda is in production and will be released in September
Click Here To Read The 2016 Agenda
 











Conference Synopsis:


Biologics Congress
Biosimilars Congress
Day 1 Track 1 -
Antibody Based Therapeutics
  • Antibody discovery & optimization
    • Bispecific antibodies
    • Monoclonal antibodies
    • Recombinant antibodies
  • Overcoming safety and risks
  • Antibody mixtures

Day 1 Track 2 -
Protein Expression, Purification & Characterisation

  • Examining different expression systems/technologies
  • Strategies to improve expression, purification, increase yields and enhance protein development
  • Difficult proteins
  • Characterization processes
  • HCP analysis
  • Cell line development

Day 2 Stream 1
Antibody-drug conjugates
development, potential & challenges

  • Optimising ADC stability & potency 
  • Optimizing payloads & linkers
  • Site specific ADCs
  • ADC design
  • Clinical updates

Antibodies for Cancer Immunotherapy

  • T cell therapy
  • Chimeric antigen receptors (CARS)
  • Immune checkpoint blockade

Day 2 Stream 2
Protein Biotherapeutics

  • Overcoming immunogenicity and aggregation issues
  • Alternative scaffolds
  • Half-life extension
  • Fusion proteins
  • Protein stability
Day 1 Track 3 - 
Development Strategy, Market Access and Commercialization
  • Developing a successful global biosimilars development strategy
  • Third wave opportunities
  • Incentives to increase uptake of biosimilars
  • Physician & patient attitudes
  • Strategies to successfully commercialize biosimilars products in Europe, USA and Emerging markets
  • Overcoming market access and commercialization barriers
    • Pricing & Reimbursement value
    • IP
  • Case Study examples





Day 2 Track 3 -
Overcoming Regulation & CMC Hurdles for Biosimilar Development
  • Current worldwide regulatory issues, updates & guidelines to obtain approval
  • Quality and CMC considerations for biosimilar development
  • Optimising cost effective manufacturing development and speed to market
  • Dealing with immunogenicity
  • Demonstrating biosimilarity
  • Optimising biosimilar clinical trial design
  • Successful Biosimilar drug case study examples










Click here to read the 2016 agenda >>



Jack Culpin
Conference Producer, the Biologics & Biosimilars Congress 2017
jack@globalengage.co.uk  
+44 (0) 1865 849841








newsletter




Register Now


















Copyright:  Global Engage Ltd.   Registered in England.  No: 6950636